** Shares of drug developer Fractyl Health GUTS.O rise 6.3% to 80 cents premarket

** Co says its patients who underwent its experimental procedure maintained ~78% of their prior GLP-1-induced weight loss at one year

** The trial tested patients with obesity who have lost at least 15% of their total body weight on a GLP-1 medication who either need or choose to discontinue GLP-1 therapy

** Co's experimental lead product Revita is an outpatient endoscopic procedure

** No procedure-related serious adverse events and no new treatment emergent adverse events were observed - GUTS

** 33% of participants continued to lose weight one year after discontinuing a GLP-1, co says

** Up to last close, stock down 65.4% YTD